A PET Study Following a Single Oral Dose of ITI-333 in Healthy Subjects
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, since the study involves healthy subjects, it is likely that participants should not be on any regular medications.
What is the purpose of this trial?
This trial tests a new drug, ITI-333, on healthy men and women to see how it affects mood and perception.
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants undergo a baseline PET/CT scan to assess initial brain receptor status
Treatment
Participants receive a single oral dose of ITI-333 followed by a postdose PET/CT scan to evaluate receptor occupancy
Follow-up
Participants are monitored for safety and pharmacokinetics up to 24 hours postdose
Treatment Details
Interventions
- ITI-333
Find a Clinic Near You
Who Is Running the Clinical Trial?
Intra-Cellular Therapies, Inc.
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborator